Lixte Biotechnology Holdings Inc

Research Lixte Biotechnology Holdings Inc (LIXT) on Bullrun: market cap USD 99.56M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerLIXT
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 99.56M
• Financial periodFY2025
• Net income-USD 6.08M

Valuation Snapshot

latest market cap is USD 99.56M.

About Lixte Biotechnology Holdings Inc

Lixte Biotechnology Holdings, Inc., a clinical-stage biopharmaceutical and proton cancer therapy company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colorectal cancer. The company's LB-100 combined with doxorubicin in advanced soft tissue sarcoma is under Phase 1b portion;

Frequently asked questions

What is Lixte Biotechnology Holdings Inc's market cap?

Lixte Biotechnology Holdings Inc's market capitalization is USD 99.56M.

What does Lixte Biotechnology Holdings Inc do?

Lixte Biotechnology Holdings, Inc., a clinical-stage biopharmaceutical and proton cancer therapy company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies.